Alternatively, if PD-L1 monotherapy is to be used within the context of cancer, rational design of new PD-L1 antibodies should consider binding properties that exclusively block PD-1–binding domain while sparing the CD80-binding domain. This evidence concerns the gene CD80 and cancer.